Investor Presentaiton
NEAR TERM FOCUS/OPPORTUNITY
Q Integration of YUTIQ into the Alimera portfolio
―
Immediate synergies led to positive adjusted EBITDA of $900,000 in quarter of acquisition
alimera
―
-
Additional synergies expected to be realized over the remainder of 2023 and in place for 2024
Revenue growth and synergies expected to yield over $20 million in adjusted EBITDA in 2024
Q Deeper and more targeted retinal physician strategy
-
Increased ILUVIEN sales reps by over 20%, YUTIQ sales reps by over 80%
-
Call points expanded by 25% to over 2600 physicians
- Expanding key account focus
Q Leverage the consistency of the two brands
-
Cross sell current ILUVIEN MDS on YUTIQ and vice versa
-
36% of ILUVIEN users not currently using YUTIQ¹
43% of YUTIQ users currently not using ILUVIEN¹
NOTE:
1. Defined as having submitted a benefit investigation in the past 6 months
Nasdaq: ALIM
15View entire presentation